{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:57Z","timestamp":1788153537028,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a highly prevalent disease and the leading cause of years lived with disability in women. The development of therapies targeting the calcitonin gene-related peptide (CGRP) pathway has provided the first mechanism-based approach for migraine prevention. Although these treatments have demonstrated substantial efficacy, 30\u201350% of patients do not achieve an adequate clinical response. This variability underscores the need of prospectively identifying responders and non-responders, thereby enabling precise treatment allocation and improving clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>BIOMIGA is a multicentre phase IV study aimed at identifying biomarkers of response to anti-CGRP therapy in migraine through integrated clinical, molecular, genetic, and neuroimaging profiling, with patients stratified according to treatment response after 3\u202fmonths treatment cycle with an mAB targeting the CGRP receptor (erenumab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individuals with episodic and chronic migraine eligible for treatment with erenumab are enrolled along with healthy control subjects. Biomarkers are collected longitudinally at baseline and at the end of a 3-month treatment with erenumab. Circulating levels of CGRP and cytokines, genetic polymorphisms, and DNA methylation are assessed. Advanced structural and functional MRI scans are performed simultaneously, and comprehensive psychometric scales are used to map central pain processing and clinical burden. The final multimodal dataset is analysed using machine learning to develop and evaluate integrated models of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Expected results<\/jats:title>\n                    <jats:p>The integration of multimodal data from patients and healthy controls, stratified according to treatment response, will enable the identification of a panel of biomarkers predictive of response to anti-CGRP therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The BIOMIGA trial represents a major step forward in the management of migraine. By combining a comprehensive multimodal profiling with a real-world, multicentre cohort of patients treated with erenumab, the study provides a framework for identifying robust biomarkers of treatment response and lays the foundation for truly individualised migraine prevention strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier NCT04503083.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1878729","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:38Z","timestamp":1788150578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab \u2013 the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project"],"prefix":"10.3389","volume":"17","author":[{"given":"Daniele","family":"Martinelli","sequence":"first","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]},{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Basedau","sequence":"additional","affiliation":[{"name":"Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Greco","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Magdalena","family":"Pocora","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]},{"name":"Brain and Behavioural Science Department, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Sch\u00f6nthaler","sequence":"additional","affiliation":[{"name":"Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Icco","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]},{"name":"Brain and Behavioural Science Department, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Vaghi","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]},{"name":"Brain and Behavioural Science Department, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sances","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascia","family":"Ghiotto","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Guaschino","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Allena","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Demartini","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Francavilla","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pichiecchio","sequence":"additional","affiliation":[{"name":"Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]},{"name":"Brain and Behavioural Science Department, University of Pavia","place":["Pavia, Italy"]},{"name":"Neuroradiology Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rut","family":"Mas-de-les-Valls","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Pareto","sequence":"additional","affiliation":[{"name":"Section of Neuroradiology, Radiology Department, Hospital Universitari Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0lex","family":"Rovira","sequence":"additional","affiliation":[{"name":"Section of Neuroradiology, Radiology Department, Hospital Universitari Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor J.","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Asskour","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Gine-Cipres","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]},{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]},{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres-Ferr\u00fas","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]},{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ballante","sequence":"additional","affiliation":[{"name":"Department of Political and Social Sciences, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Castellazzi","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mehnert","sequence":"additional","affiliation":[{"name":"Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"May","sequence":"additional","affiliation":[{"name":"Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR)","place":["Barcelona, Spain"]},{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[{"name":"Headache Science and Rehabilitation Unit, IRCCS C. Mondino Foundation","place":["Pavia, Italy"]},{"name":"Brain and Behavioural Science Department, University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the global burden of disease study 2023","volume":"24","author":"Collaborators","year":"2025","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","article-title":"Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives","volume":"405","author":"Versijpt","year":"2025","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11916-025-01365-4","article-title":"Review: an update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine","volume":"29","author":"Nicol","year":"2025","journal-title":"Curr Pain Headache Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241305381","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine","volume":"45","author":"Ornello","year":"2025","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","article-title":"CGRP-targeted medication in chronic migraine - systematic review","volume":"25","author":"Oliveira","year":"2024","journal-title":"J Headache Pain"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"jnnp-2023-333295","DOI":"10.1136\/jnnp-2023-333295","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"95","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1474-4422(25)00477-6","article-title":"Advances in migraine prevention","volume":"25","author":"Martinelli","year":"2026","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12883-023-03302-7","article-title":"Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine","volume":"23","author":"Siersbaek","year":"2023","journal-title":"BMC Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-024-01727-0","article-title":"Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population","volume":"25","author":"Lazaro-Hernandez","year":"2024","journal-title":"J Headache Pain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/ene.14431","article-title":"Estimating the savings associated with a migraine-free life: results from the Spanish atlas","volume":"27","author":"Irimia","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"108523","DOI":"10.1016\/j.pharmthera.2023.108523","article-title":"Towards precision medicine in migraine: recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response","volume":"250","author":"Juhasz","year":"2023","journal-title":"Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065334","article-title":"Biomarkers of migraine: an integrated evaluation of preclinical and clinical findings","volume":"24","author":"Demartini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0333102420974359","article-title":"How does the brain change in chronic migraine? Developing disease biomarkers","volume":"41","author":"Pozo-Rosich","year":"2021","journal-title":"Cephalalgia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-020-01189-0","article-title":"Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?","volume":"21","author":"Greco","year":"2020","journal-title":"J Headache Pain"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-024-01769-4","article-title":"Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience","volume":"25","author":"Garate","year":"2024","journal-title":"J Headache Pain"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s10571-023-01387-9","article-title":"The role of MicroRNA in migraine: a systemic literature review","volume":"43","author":"Grodzka","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s10194-024-01787-2","article-title":"MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment","volume":"25","author":"Ornello","year":"2024","journal-title":"J Headache Pain"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/brain\/awaf005","article-title":"Composite microRNA-genetic risk score model links to migraine and implicates its pathogenesis","volume":"148","author":"Chen","year":"2025","journal-title":"Brain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-024-01946-5","article-title":"A robust multimodal brain MRI-based diagnostic model for migraine: validation across different migraine phases and longitudinal follow-up data","volume":"26","author":"Namgung","year":"2025","journal-title":"J Headache Pain"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"11795735231205413","DOI":"10.1177\/11795735231205413","article-title":"Functional MRI and diffusion tensor imaging in migraine: a review of migraine functional and white matter microstructural changes","volume":"15","author":"Chou","year":"2023","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-015-0576-7","article-title":"DNA methylation of RAMP1 gene in migraine: an exploratory analysis","volume":"16","author":"Wan","year":"2015","journal-title":"J Headache Pain"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13148-023-01604-8","article-title":"Alterations in DNA methylation associate with reduced migraine and headache days after medication withdrawal treatment in chronic migraine patients: a longitudinal study","volume":"15","author":"Mehta","year":"2023","journal-title":"Clin Epigenetics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119127","article-title":"The epigenetics of migraine","volume":"24","author":"Zobdeh","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193092","article-title":"Antagonism of CGRP receptor: central and peripheral mechanisms and mediators in an animal model of chronic migraine","volume":"11","author":"Greco","year":"2022","journal-title":"Cells"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"26481","DOI":"10.1038\/s41598-024-78332-3","article-title":"The search for non-evoked markers of pain in the GTN mouse model of migraine","volume":"14","author":"Clement","year":"2024","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1111\/ene.15458","article-title":"Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: a multicenter Spanish study","volume":"29","author":"Gonzalez-Martinez","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1474-4422(24)00003-6","article-title":"Potential treatment targets for migraine: emerging options and future prospects","volume":"23","author":"Chiang","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3331024241262751","DOI":"10.1177\/03331024241262751","article-title":"An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine","volume":"44","author":"Romozzi","year":"2024","journal-title":"Cephalalgia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14010085","article-title":"The clinical relevance of artificial intelligence in migraine","volume":"14","author":"Torrente","year":"2024","journal-title":"Brain Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/0333102411408359","article-title":"A subjective cognitive impairment scale for migraine attacks. The MIG-SCOG: development and validation","volume":"31","author":"Gil-Gouveia","year":"2011","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: the HIT-6","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"key":"ref32","volume-title":"Beck Depression Inventory\u2013II (BDI-II). APA PsycTests","author":"Beck","year":"1996"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","article-title":"Development and validation of the migraine-specific quality of life questionnaire","volume":"38","author":"Jhingran","year":"1998","journal-title":"Headache"},{"key":"ref35","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2025"},{"key":"ref36","first-page":"e70120","article-title":"Exploring the association of migraine susceptibility SNPs with the risk of chronic migraine","volume-title":"Eur J Pain","author":"Cargnin","year":"2025"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/head.12559","article-title":"Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache","volume":"55","author":"Cargnin","year":"2015","journal-title":"Headache"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/ene.15236","article-title":"Clinic and genetic predictors in response to erenumab","volume":"29","author":"Zecca","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3331024251318016","DOI":"10.1177\/03331024251318016","article-title":"Guidelines of the international headache Society for Real-World Evidence studies in migraine and cluster headache","volume":"45","author":"Pozo-Rosich","year":"2025","journal-title":"Cephalalgia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12911-017-0434-4","article-title":"Automatic migraine classification via feature selection committee and machine learning techniques over imaging and questionnaire data","volume":"17","author":"Garcia-Chimeno","year":"2017","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref41","first-page":"81","volume-title":"Induction of Decision Trees: Machine Learning","author":"Quinlan","year":"1986"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1006\/jcss.1997.1504","article-title":"A decision-theoretic generalization of on-line learning and an application to boosting","volume":"55","author":"Freund","year":"2002","journal-title":"J Comput Syst Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"109366","DOI":"10.1016\/j.intimp.2022.109366","article-title":"Erenumab efficacy in migraine headache prophylaxis: a systematic review","volume":"117","author":"Bagherzadeh-Fard","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1177\/0333102419847751","article-title":"Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults","volume":"39","author":"Deen","year":"2019","journal-title":"Cephalalgia"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults","volume":"40","author":"Diener","year":"2020","journal-title":"Cephalalgia"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","article-title":"Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study","volume":"101","author":"Barbanti","year":"2023","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","article-title":"Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study","volume":"271","author":"Barbanti","year":"2024","journal-title":"J Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s10194-025-02205-x","article-title":"Preanalytical stability of plasma calcitonin gene-related peptide: clinical and research implications","volume":"26","author":"Frank","year":"2025","journal-title":"J Headache Pain"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241291578","article-title":"High-frequency episodic migraine: time for its recognition as a migraine subtype?","volume":"44","author":"Cammarota","year":"2024","journal-title":"Cephalalgia"},{"key":"ref51","first-page":"1","article-title":"The International Classification of Headache Disorders, 3rd edition","volume-title":"Cephalalgia","year":"2018"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","article-title":"The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis","volume":"24","author":"Lampl","year":"2023","journal-title":"J Headache Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1878729\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:39Z","timestamp":1788150579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1878729\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":52,"alternative-id":["10.3389\/fneur.2026.1878729"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1878729","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1878729"}}